Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age.
Simon J Johnston, Binafsha M Syed, Ruth M Parks, Cíntia J Monteiro, Joseph A Caruso, Andrew R Green, Ian O Ellis, Kelly K Hunt, Cansu Karakas, Khandan Keyomarsi and 1 more
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 3 countries.
Simon J JohnstonNottingham Breast Cancer Research Centre, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK.
Binafsha M SyedNottingham Breast Cancer Research Centre, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK.
Ruth M ParksNottingham Breast Cancer Research Centre, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0003-3832-7431
Cíntia J MonteiroNottingham Breast Cancer Research Centre, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK.
Joseph A CarusoDepartment of Pathology, University of California, San Francisco, CA 94143, USA.
Andrew R GreenNottingham Breast Cancer Research Centre, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-0488-5913
Ian O EllisNottingham Breast Cancer Research Centre, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK.
Kelly K HuntDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-9156-8723
Cansu KarakasDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Khandan KeyomarsiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kwok-Leung CheungNottingham Breast Cancer Research Centre, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0003-2973-0755
University of Nottingham · GBThe University of Texas MD Anderson Cancer Center · USLiaquat University of Medical & Health Sciences · PKUniversity of California, San Francisco · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Cytoplasmic cyclin E is an early event for progression to invasive breast cancerR01CA223772 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KEYOMARSI, KHANDAN · 2018 to 2023
$2.3M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA223772
6 · The paper itself
Abstract
Multi-cohort analysis demonstrated that cytoplasmic cyclin E expression in primary breast tumors predicts aggressive disease. However, compared to their younger counterparts, older patients have favorable tumor biology and are less likely to die of breast cancer. Biomarkers therefore require interpretation in this specific context. Here, we assess data on cytoplasmic cyclin E from a UK cohort of older women alongside a panel of >20 biomarkers. Between 1973 and 2010, 813 women ≥70 years of age underwent initial surgery for early breast cancer, from which a tissue microarray was constructed (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. · full record | OpenQuestion